Norgestimate and Ethinyl Estradiol Tablets-Triphasic Regimen Articles
Barr's profits up 24% to $76M
15 May 2006
Barr 2nd-qtr turnover rockets 79%
16 February 2004
Barr introduces generic Tri-Cyclen
5 January 2004
Showing 1-3 of 3 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
